Scientific Program

2nd International Conference on



Medicinal Chemistry & Computer Aided Drug Designing October 15-17, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA



"Organize your Events at OMICS Group Conferences"

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to symposia@omicsonline.org

OMICS Group Conferences

5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499 Email: medchem2013@omicsonline.net

Salon A



08:30-08:55

Opening Ceremony

Keynote Forum						
09:55-10:00	Introduction					
10:00-10:25	James K. Bashkin					
	University of Missouri-St. Louis, USA					
10:25-10:50	Brian S. J. Blagg					
	The University of Kansas, USA					
	Coffeebreak: 10:50-11:05 @ Foyer					
11:05-11:30	Xiang-Qun (Sean) Xie					
	University of Pittsburgh, USA					
11:30-11:55	Tulay Aygan Atesin					
	The University of Texas-Pan American, USA					

Track 1: Rational Drug Designing

Session Chair: Victor J Hruby, University of Arizona, USA Session Co-Chair: Alexander Heifetz, Evotec (UK) Ltd., UK

Session Introduction

Design and investigation of multivalent ligands for the detection and treatment of diseases 11:55-12:15

Victor J Hruby, University of Arizona, USA

12:15-12:35 Structure-based drug discovery for GPCRs: From receptors to ligands

Alexander Heifetz, Evotec (UK) Ltd., UK

DNA-binding polyamides designed against E1, E2 binding sites of HPV DNA show dramatic anti-HPV activity in cell and tissue culture

James K Bashkin, University of Missouri-St. Louis, USA

12:55-13:15 Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction Xiaoqi Chen, Amgen, USA

Lunch Break 13:15-14:00 @ Carol & Patio

The design and discovery of CXCR4 chemokine receptor antagonists through incorporation of GPCR-MedChem based fragments 14:00-14:20

Larry Wilson, Emory University and Emory Institute for Drug Development, USA

Understanding the essential requirements for success in structure-based design 14:20-14:40

Gregory L Warren, OpenEye Scientific Software, USA

Site Identification by Ligand Competitive Saturation (SILCS): Computational approach for the identification and optimization of ligands targeting proteins,

14:40-15:00 RNA and other macromolecules

Alexander D MacKerell, University of Maryland, USA

Computer-aided design of glucokinase activators Meihua Tu, Pfizer, USA 15:00-15:20

Non-competitive regulation of the human proteasome by natural products and natural product inspired scaffolds 15:20-15:40

Jetze J Tepe, Michigan State University, USA

Coffee Break 15:40-15:55 @ Foyer

Rational design approaches to find novel ligands targeting the aryl hydrocarbon receptor: successful applications and mechanistic studies 15:55-16:15

William H Bisson, Oregon State University, USA

Modulations of protein-protein interactions of EGFRs: Structure, inhibition, dynamics and its implications in breast cancer 16:15-16:35

Seetharama D. Satyanarayanajois, University of Louisiana at Monroe, USA

16:35-16:55 Development of new antibiotics by targeting essential enzymes in bacteria: Structure-based design and simulation studies Concepción González-Bello, Universidad de Santiago de Compostela, Spain

Design and synthesis of novel pyrimidone analogues as HIV-1 integrase inhibitors

16:55-17:15

Guisen Zhao, Shandong University, China

Synthesis and anti-candida activity evaluation of new [1,2,4] triazolo[3,4-b][1,3,4] thiadiazines

Mashooq Ahmad Bhat, King Saud University, Kingdom of Saudi Arabia Newer approaches to the discovery of glitazones

 $\textbf{Praveen Thaggikuppe Krishnamurthy,} \ \mathsf{JSS} \ \mathsf{College} \ \mathsf{of} \ \mathsf{Pharmacy,} \ \mathsf{India}$ 18:30-19:30 Cocktails Sponsored by Medicinal Chemistry @ Foyer

Tahiti

Track 2: Computer-Aided Drug Design and Structure Determination

Session Chair: Istvan J. Enyedy, Biogen Idec, USA

17:35-17:55

Session Co-Chair: Nicolas Moitessier, McGill University, Canada

Session Introduction

New approaches to "Hit" optimization 11:55-12:15

Istvan J. Enyedy, Biogen Idec, USA

12:15-12:35 Accurate binding site models can be derived from low quality PDB files using an empirical geometry based force field Colin McMartin, Thistlesoft, USA

Integrating computational approaches into high throughput screening for rational drug discovery

Xin Hu, National Center for Advancing Translational Sciences, National Institutes of Health, USA

Using side-chain models derived from atomic resolution X-ray crystallography to develop force fields which can predict global energy minimum 12:55-13:15 geometries Regine S Bohacek, BostondeNovo, USA Lunch Break 13:15-14:00 @ Carol & Patio Forecaster: A computational tool for drug design and discovery developed by experimentalists for experimentalists 14:00-14:20 Nicolas Moitessier, McGill University, Canada Genes to Leads: A rational structure guided lead discovery technology that works for both enzymes and protein-protein interaction targets 14:20-14:40 Kal Ramnarayan, Sapient Discovery, LLC, USA Discovery of highly-potent and selective inhibitors for the ABCG2 transporter 14:40-15:00 Achene Boumedjel, Université Joseph Fourier de Grenoble, France Predictive application of bioisostere transformations to identify novel high quality compound ideas 15:00-15:20 Matthew Segall, Optibrium Ltd., UK Novel sildenafil analogues: Possible drugs for increased sensitivity to chemotherapeutic agents 15:20-15:40 Aina Westrheim Ravna, University of Tromso, Norway Coffee Break 15:40-15:55 @ Foyer Structural insights of SIR2 proteins from T. cruzi as promising targets to fight against Chagas disease 15:55-16:15 Alessandra Nurisso, University of Geneva-University of Lausanne, Switzerland Stratification of surface lysine residues of bovine testicular hyaluronidase on the base of its 3D structure model: Computer aided drug designing of 16:15-16:35 chondroitin sulphate modified enzyme derivative Alexander V. Maksimenko, Institute of Experimental Cardiology, Russia 18:30-19:30 Cocktails Sponsored by Medicinal Chemistry @ Foyer October 16, 2013 Day 2 Salon B Track 3: Quantitative Structure-Activity Relationships Track 4: Drug Development and Delivery System Track 6: Drug Interactions Track 8: Pharmacognosy Session Chair: Tatsuya TAKAGI, Osaka University, Japan Session Co-Chair: Cesar M Compadre, University of Arkansas for Medical Sciences, USA Session Introduction In Silico screening for anti-HPV agents using docking studies Tatsuya TAKAGI, Osaka University, Japan The development of the tocoflexols, a series of novel vitamin E analogues with enhanced bioavailability 09:20-09:40 Cesar M Compadre, University of Arkansas for Medical Sciences, USA 09:40-10:00 New polymeric "ruthenium-cyclopentadienyl" complexes for drug delivery in cancer therapy Andreia Valente, Universidade de Lisboa, Portugal 10:00-10:20 Unraveling the human multidrug resistance p-glycoprotein poly-specificity Pierre Falson, Institute of Biology and Chemistry of Proteins, France Coffee Break 10:20-10:35 @ Foyer PK modulation of haptenylated peptides via non-covalent antibody complexation 10:35-10:55 Stefan Dengl, Roche Diagnostics GmbH, Germany Tumour active plant derived compounds in combination with targeted therapy towards overcoming drug resistance in ovarian cancer Fazlul Huq, The University of Sydney, Australia 11:15-11:35 Designed monofunctional platinums found to have significant antitumor activity Laila Arzuman, The University of Sydney, Australia 11:35-11:55 A phytochemical and biological investigation of aloe grandidentata salm.-Dyck Taghreed Abdou Ibrahim, King Saud University, Saudi Arabia Docking guided QSAR study on a series of N-acetamideindolecarboxylic acid derivatives acting as HCV NS 5B polymerase inhibitors 11:55-12:15 Vaishali M. Patil, Bharat Institute of Technology, India Track 5: Drug Discovery Session Chair: Gerard Rosse, Dart Neuroscience, USA Session Co-Chair: Craig M Williams, University of Queensland, Australia Session Introduction Innovative approaches to expand medicinal chemistry space 12:15-12:35 Gerard Rosse, Dart Neuroscience, USA Lunch Break 12:35-13:20 @ Carol & Patio Discovery of a first-in-class topically bioavailable kit inhibitor with clinical activity using computational chemogenomics technology 13:20-13:40 James Hendrix, nPharmakon LLC, USA Discovery of a small molecule direct keap1-Nrf2 inhibitor as an anti-oxidant inflammation modulator 13:40-14:00 Magesh Sadagopan, Otsuka Maryland Medicinal Laboratories, Inc., USA Can cubane act as a benzene isostere? 14:00-14:20 Craig M Williams, University of Queensland, Australia Research and development on novel antitumor agents: Preparation, evaluation, and mechanism of low-molecular-weighted phospha sugar 14:20-14:40 derivatives as IER5/Cdc25B targeted antileukemic agents Mitsuji YAMASHITA, Shizuoka University, Japan Modulators of FGF-FGFR-Heparan sulfate complex: identifications of allosteric antagonists and oligosaccharide agonists as potential novel therapeutics 14:40-15:00 Gilbert Lassalle, Sanofi Aventis, France Chemistry, bioactivity, and computational prediction of binding modes for sarsolenane and capnosane diterpenes as PTP1B inhibitors from the 15:00-15:20 hainan soft coral Sarcophyton trocheliophorum marenzeller Yue-Wei Guo, Shanghai Institute of Materia Medica, China Coffee Break 15:20-15:35 @ Foye 15:35-15:55 On the field of metallodrugs-new ruthenium compounds as anti-tumor agents Ana Isabel Tomaz, Universidade de Lisboa, Portugal 15:55-16:15 Design, synthesis and antidiabetic, cardiomyopathy studies of cinnamic acid-amino acid hybrid analogs Subir Samanta, Birla Institute of Technology, India 16:15-16:35 Synthesis and screening of newer quinazolin-3(h)-4-One derivatives for anticonvulsant activity Jayasekhar P Nair, Oman Medical College, Sultanate of Oman

Drug profile matching- drug discovery by polypharmacology-based interaction profiling

Zoltan Simon, Eotvos Lorand University, Hungary

16:35-16:55

Pavel Mykhailiuk, Enamine Ltd., Ukraine

Tahiti

Track 19	Docont	Docomerel	s and F	evelonment)	

Session Chair: John Spencer, University of Sussex, UK Session Co-Chair: Carsten Detering, BioSolvelT Inc, USA

Session Introduction

09:00-09:20 Synthesis and evaluation of some novel thiazolidinedione derivatives as PPAR-α/γ dual agonist

Praveen Thaggikuppe Krishnamurthy, JSS College of Pharmacy, India

09:20-09:40 Unleash the power of the amygdala: How to incorporate MedChem know-how early on in the CADD lead optimization phase

Carsten Detering, BioSolvelT Inc., USA

Drug discovery: Hit to lead, lead to possible clinical candidates-development of androgen receptor down-regulating agents for the treatment of

09:40-10:00 castration resistant prostate cancer

Purushottamachar Puranik, University of Maryland School of Medicine, USA

10:00-10:20 Synthesis of privileged structure libraries for biological evaluation John Spencer, University of Sussex, UK

Coffee Break 10:20-10:35 @ Foyer

Design, synthesis and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms 10:35-10:55

Jean Leandro Dos Santos, State University of Sao Paulo, Brazil

Evaluation of serum levels of cadmium and lead in occupationally exposed painters with administration of probiotic (Lactobacillus pentosus kca 1)

10:55-11:15 supplemented yogurt: A pilot study

Osadolor H. B, University of Benin, Nigeria

11:15-11:35 Lipid pattern in serum of patients with type 2 diabetes mellitus Ashur S Eljamil, Tripoli University, Libya

11:35-11:55 What can we expect from new therapeutic strategies in nano-pharmacology and nano-medicine?

Hans-Christian Siebert, Research Institute for Bioinformatics and Nanotechnology (RI-B-NT), Germany

11:55-12:15 Mitochondria specific antioxidants and their derivatives in the context of the drug development for neuro degeneration and cancer Gjumrakch Aliev, GALLY International Biomedical Research Consulting LLC, USA

15:30-16:30 Poster Presentations @ Carol & Patio

18:30-19:30 Cocktails Sponsored by Drug Designing: Open Access @ Foyer

October 17, 2013 Day 3

Track 10: Receptors and Inhibitors

Session Chair: Prabagaran Narayanasamy, University of Nebraska Medical Center, USA

Session Co-Chair: Xiang-Qun (Sean) Xie, University of Pittsburgh, USA

Session Introduction

The Hsp90 C-terminal binding site, instructions for and ramifications of inhibition 09:00-09:20

Brian S. J. Blagg, The University of Kansas, USA

Inhibition of prostanoid receptor EP2: A novel anti-inflammatory therapy for chronic neurodegenerative and autoimmune diseases 09:20-09:40

Thota Ganesh, Emory University School of Medicine, USA

Selective vitamin K2 biosynthesis inhibitors to treat non-replicating Mycobacterium tuberculosis 09:40-10:00

Michio Kurosu, University of Tennessee Health Science Center, USA

Inhibitors of fatty acid amide hydrolase (FAAH): SAR and results in pre-clinical pain models

10:00-10:20 J. Guy Breitenbucher, Dart Neuroscience LLC, USA

Coffee Break 10:20-10:35 @ Foyer

Discovery of novel bicyclic derivatives to stop the growth of mycobacterium tuberculosis by Inhibiting MenA 10:35-10:55

Prabagaran Narayanasamy, University of Nebraska Medical Center, USA

10:55-11:15 The synthesis of potential inhibitors of panthothenate synthetase Kellie L Tuck, Monash University, Australia

11:15-11:35 Design and synthesis of inhibitors of cysteine protease Debatosh Majumdar, Glycosyn LLC, USA

11:35-11:55 Inward rectifier potassium channels as emerging drug targets

Jerod S. Denton, Vanderbilt University School of Medicine, USA

11:55-12:15 Identification of a new class of SUMO specific protease 2 inhibitors utilizing structure based virtual screening approach
Ashutosh Kumar, Zhang Initiative Research Unit, RIKEN, Japan

Are D-neurons and trace amine-associated receptor, Type 1 involved in mesolimbic dopamine hyperactivity of schizophrenia? 12:15-12:35

Keiko Ikemoto, Fukushima Medical University, Japan

Lunch Break 12:35-13:20 @ Carol & Patio

13:20-13:40 Harnessing human N-type Ca2+ channel receptor by identifying the atomic hotspot regions for its blocker design

C. Gopi Mohan, Amrita Vishwa Vidyapeetham University, India


13:40-14:00 Discovery of small molecule inhibitors of protein-protein interactions using DNA-encoded chemical libraries

Nils Jakob Vest Hansen, Vipergen ApS, Denmark

14:00-14:20 Post-marketing surveillance of active pharmaceutical ingredients in antimalarial drugs used in Malawi

Ibrahim Chikowe, University of Ghana, Ghana

Bookmark your dates



Proup Medicinal Chemistry & mputer Aided Drug Designing

August 18-20, 2014 Beijing, China

OMICS Group Inc.

Conferences Accelerating Scientific Discovery

2360 Corporate Circle, Suite 400 Henderson, NV 89074-7722, USA Ph: +1-888-843-8169 Fax: +1-650-618-1417 omicsonline@omicsonline.com

OMICS Publishing Group 5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA Ph: +1-650-268-9744 Fax: +1-650-618-1414

omicsonline@omicsonline.org

OMICS Group SEZ Unit, Building No. 20, 9th Floor

APIIC Layout, HITEC City Hyderabad-500081, AP, INDIA Ph: 040-40131823, 040-47482222 omicsgroup@omicsgroup.org

Toll free

USA & Canada: 1-800-216-6499 Australia: 1-800-651-097 Europe: 0805-080048